Page last updated: 2024-12-05

w 12

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

W 12: calmodulin antagonist; W13 analog with Cl deleted from benzene ring [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4298
CHEBI ID93373
SCHEMBL ID1928807
MeSH IDM0119785

Synonyms (14)

Synonym
BRD-K78084463-003-01-0
HSCI1_000226
w 12
n-(4-aminobutyl)-2-naphthalenesulfonamide
35517-12-5
w-12
2-naphthalenesulfonamide, n-(4-aminobutyl)-
n-(4-aminobutyl)naphthalene-2-sulfonamide
w-12 hydrochloride
SCHEMBL1928807
CHEBI:93373
Q27165078
DTXSID20956914
AKOS040754382

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" tDCS- and/or rTMS-related adverse events appeared slightly and briefly."( Efficacy and safety of simultaneous rTMS-tDCS over bilateral angular gyrus on neuropsychiatric symptoms in patients with moderate Alzheimer's disease: A prospective, randomized, sham-controlled pilot study.
Ding, Y; Hu, Y; Huang, Z; Jia, Y; Liu, C; Sun, Y; Wang, Y,
)
0.13
" Serious treatment-emergent adverse events were infrequent, reported by 2%, 1%, and 0% of those receiving fezolinetant 30 mg, fezolinetant 45 mg, and placebo, respectively."( Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
English, M; Franklin, C; Johnson, KA; Lee, M; Martin, N; Nappi, RE; Neal-Perry, G; Santoro, N; Shapiro, M; Stute, P; Thurston, RC; Wolfman, W, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" The dose-response curve for HL-60 differentiation was consistent with the published 50% inhibitory dose for inhibition of calmodulin-activated phosphodiesterase and with the calmodulin drug-binding potential of N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide and N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide and their less active congeners, N-(6-aminohexyl)-1-naphthalenesulfonamide and N-(4-aminobutyl)-2-naphthalenesulfonamide."( Induction of myeloid differentiation of HL-60 cells with naphthalene sulfonamide calmodulin antagonists.
Branch, ME; Niedel, J; Sedwick, WD; Veigl, ML, 1986
)
0.27
"Data from 31 children with IBD [4-18 years] receiving standard infliximab induction dosing (5 mg/kg at week [w]0, w2 and w6) were repurposed."( A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases.
Dreesen, E; Ferrante, M; Hoffman, I; Kantasiripitak, W; Thomas, D; van Hoeve, K; Vermeire, S; Wicha, SG, 2023
)
0.91
"A freely available, multi-model MIPD tool facilitates infliximab induction dosing and improves deep remission rates in children with IBD."( A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases.
Dreesen, E; Ferrante, M; Hoffman, I; Kantasiripitak, W; Thomas, D; van Hoeve, K; Vermeire, S; Wicha, SG, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
sulfonic acid derivative
naphthalenesAny benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (24.32)18.7374
1990's8 (21.62)18.2507
2000's6 (16.22)29.6817
2010's0 (0.00)24.3611
2020's14 (37.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 76.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index76.79 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index131.41 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (76.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (2.50%)0.25%
Other34 (85.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]